Carna Biosciences and Enamine Sign Collaboration Agreement
News May 19, 2006
Enamine is responsible for developing kinase-focused libraries against targeted kinase utilizing docking methodologies and Carna Biosciences is responsible for screening the libraries against the targeted kinase.
The companies intend to license the lead compounds developed by the collaboration to pharmaceutical companies.
"By collaborating with Enamine, Carna Biosciences will be able to find novel lead compounds attractive for pharmaceutical companies," said Kohichiro Yoshino, President and CEO of Carna Biosciences.
"The unsurpassed quality and reliability of our assay and screening technologies will help us, together with Enamine's know-how on development of compound libraries, to continue the expansion of our kinase-focused drug discovery businesses."
"Our expertise in the computer assisted structure-based techniques combined with original custom tailored chemistry will result in novel lead compounds," said Dr. Andrei Tolmachev, President and CEO of Enamine.
"The technologies of Carna Biosciences and Enamine are so complementary that I am confident in the outcome of this collaborative research."
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE